Literature DB >> 7789096

In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci.

C Freeman1, A Robinson, B Cooper, M Mazens-Sullivan, R Quintiliani, C Nightingale.   

Abstract

The results of susceptibility testing of 48 phenotyped strains of glycopeptide antibiotic-resistant enterococci are reported. Minimum inhibitory and bactericidal concentrations (MICs and MBCs) were determined for 27 vanA, 17 vanB, and 4 vanC strains. Antibiotics exhibiting the greatest activity included novobiocin (MIC90 = 8 micrograms/ml and MBC90 = 32 micrograms/ml), ramoplanin (MIC90 = 2 micrograms/ml and MBC90 = 4 micrograms/ml), and the streptogramin RP59500 (MIC90 = 4 micrograms/ml and MBC90 = 32 micrograms/ml). These antibiotics warrant further investigation as potentially useful agents, either alone or in combination, for treating enterococcal infections.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7789096     DOI: 10.1016/0732-8893(94)00113-b

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  9 in total

Review 1.  Trovafloxacin.

Authors:  M Haria; H M Lamb
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 2.  Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci.

Authors:  M G Cormican; R N Jones
Journal:  Drugs       Date:  1996       Impact factor: 9.546

3.  Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.

Authors:  G M Eliopoulos; C B Wennersten; H S Gold; T Schülin; M Souli; M G Farris; S Cerwinka; H L Nadler; M Dowzicky; G H Talbot; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 4.  Quinupristin-dalfopristin.

Authors:  H M Bryson; C M Spencer
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

Review 5.  Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.

Authors:  R G Finch
Journal:  Drugs       Date:  1996       Impact factor: 9.546

6.  Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.

Authors:  F Caron; H S Gold; C B Wennersten; M G Farris; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

Review 7.  Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.

Authors:  J C Pechère; T D Gootz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

Review 8.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

9.  Glycopeptide resistance in gram-positive cocci: a review.

Authors:  S Sujatha; Ira Praharaj
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-06-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.